Cancer. Malignant neoplasms
Conditions
Interventions
Intervention 1: Patients in drug group will be received Vitamin E (Zahravi Pharmaceutical company, Tabriz, Iran), 400Iu daily for 21 days starting before cisplatin treatment for 4 cycles. Intervention
Treatment - Drugs
Placebo
Patients in drug group will be received Vitamin E (Zahravi Pharmaceutical company, Tabriz, Iran), 400Iu daily for 21 days starting before cisplatin treatment for 4 cycles
Patients in control group will be received placebo of Vitamin E (Zahravi Pharmaceutical company, Tabriz, Iran), 400Iu daily for 21 days starting before cisplatin treatment for 4 cycles
Sponsors
Vice Chancellor for Research,Isfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria were age = 18 years old and having glomerular filtration rate (GFR) > 80 ml/min. Exclusion criteria were comorbidity that affected renal function (such as diabetes mellitus, hypertension, and past history of renal dysfunction); previous chemotherapy and treatment with other supplementation.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in serum creatinine and the glomerular filtration rate. Timepoint: From cycle 1 to 4. Method of measurement: laboratory. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in neutrophil gelatinase-associated lipocalin (NGAL) levels. Timepoint: From cycle 1 to 4. Method of measurement: Elisa kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Sarah Mousavi
Isfahan University of Medical Science
Outcome results
None listed